Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate. 1979

C W Vose, and J K Butler, and B M Williams, and J E Stafford, and J R Shelton, and D A Rose, and R F Palmer, and A M Breckenridge, and M L Orme, and M J Serlin

Measurement by radioimmunoassay of plasma norethisterone (NE) has been used to compare the bioavailability of tablets containing ethynodiol diacetate (EDA) with that of a standard oral solution of this progestogen in 12 normal women. The tablets investigated were from three batches which showed different in vitro dissolution rates. There were no significant differences in the bioavailability of the tablet formulations, which were essentially bioequivalent to the solution. Peak blood levels of NE were reached within 4h of EDA administration in solution or tablets. After the peak, NE plasma levels declined in two phases, with a mean terminal elimination half lives of 4 to 6.9h. The pharmacokinetics of NE after EDA administration showed some similarity to those observed by other workers after oral doses of NE itself.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009640 Norethindrone A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION. 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17alpha)-,Ethinylnortestosterone,Norethisterone,Norpregneninolone,Conceplan,Micronor,Monogest,Nor-QD,Norcolut,Norcolute,Norethindrone, (1 beta)-Isomer,Norlutin,Nor QD,NorQD
D005040 Ethynodiol Diacetate A synthetic progestational hormone used alone or in combination with estrogens as an oral contraceptive (CONTRACEPTIVES, ORAL). 19-Norpregn-4-en-20-yne-3,17-diol, diacetate, (3beta,17alpha)-,(3 beta, 17 alpha)-19-Norpregn-4-en-20-yne-3,17 diol Diacetate,Continuin,Ethyndiol Diacetate,Ethynodiol Diacetate, (17 alpha)-Isomer,Femulen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

C W Vose, and J K Butler, and B M Williams, and J E Stafford, and J R Shelton, and D A Rose, and R F Palmer, and A M Breckenridge, and M L Orme, and M J Serlin
February 1977, Journal of steroid biochemistry,
C W Vose, and J K Butler, and B M Williams, and J E Stafford, and J R Shelton, and D A Rose, and R F Palmer, and A M Breckenridge, and M L Orme, and M J Serlin
May 1972, Xenobiotica; the fate of foreign compounds in biological systems,
C W Vose, and J K Butler, and B M Williams, and J E Stafford, and J R Shelton, and D A Rose, and R F Palmer, and A M Breckenridge, and M L Orme, and M J Serlin
June 1985, Contraception,
C W Vose, and J K Butler, and B M Williams, and J E Stafford, and J R Shelton, and D A Rose, and R F Palmer, and A M Breckenridge, and M L Orme, and M J Serlin
January 1983, Hormone research,
C W Vose, and J K Butler, and B M Williams, and J E Stafford, and J R Shelton, and D A Rose, and R F Palmer, and A M Breckenridge, and M L Orme, and M J Serlin
December 1966, British medical journal,
C W Vose, and J K Butler, and B M Williams, and J E Stafford, and J R Shelton, and D A Rose, and R F Palmer, and A M Breckenridge, and M L Orme, and M J Serlin
January 1982, Hormone research,
C W Vose, and J K Butler, and B M Williams, and J E Stafford, and J R Shelton, and D A Rose, and R F Palmer, and A M Breckenridge, and M L Orme, and M J Serlin
February 1968, The Medical journal of Australia,
C W Vose, and J K Butler, and B M Williams, and J E Stafford, and J R Shelton, and D A Rose, and R F Palmer, and A M Breckenridge, and M L Orme, and M J Serlin
March 1968, The Medical journal of Australia,
C W Vose, and J K Butler, and B M Williams, and J E Stafford, and J R Shelton, and D A Rose, and R F Palmer, and A M Breckenridge, and M L Orme, and M J Serlin
March 1976, European journal of clinical pharmacology,
C W Vose, and J K Butler, and B M Williams, and J E Stafford, and J R Shelton, and D A Rose, and R F Palmer, and A M Breckenridge, and M L Orme, and M J Serlin
April 1966, Lyon medical,
Copied contents to your clipboard!